Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06275360 · ClinicalTrials.gov registry record · Phase 2
Repositioning Immunotherapy in VetArans With Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer, sponsored by VA Office of Research and Development.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 25
- Enrollment target
- 7
- Study locations
NCT06275360 is a Phase 2 study of Non-Small Cell Lung Cancer that is actively recruiting participants, run by VA Office of Research and Development. The registered enrollment target is 25 participants, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (96% lower). The trial reports 7 study locations across 7 states.
The verdict
NCT06275360, a Phase 2 study of Non-Small Cell Lung Cancer, is actively recruiting participants, sponsored by VA Office of Research and Development.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 25 participants
- Enrollment target
- 7
- Study locations
Study Summary
This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
Conditions Studied
Interventions
- DRUG Nivolumab
Study Locations (7)
Connecticut
- VA Connecticut Healthcare System West Haven Campus, West Haven, CT - West Haven
District of Columbia
- VA Central Office, Washington, DC - Washington D.C.
Indiana
- Richard L. Roudebush VA Medical Center, Indianapolis, IN - Indianapolis
Michigan
- VA Ann Arbor Healthcare System, Ann Arbor, MI - Ann Arbor
Nebraska
- Omaha VA Nebraska-Western Iowa Health Care System, Omaha, NE - Omaha
Texas
- Michael E. DeBakey VA Medical Center, Houston, TX - Houston
Virginia
- Richmond VA Medical Center, Richmond, VA - Richmond
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2024-03-01 |
| Est. Completion | 2030-03-31 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06275360
The ClinicalTrials.gov registry entry for NCT06275360 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 25 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 659-participant average among 449 other Non-Small Cell Lung Cancer trials with a reported enrollment target (96% lower). The listed sponsor is VA Office of Research and Development, which has 1,668 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 1 intervention - of which Nivolumab is the first listed.
NCT06275360 reports 7 study locations spanning 7 distinct geographic areas - top geographies include Connecticut, District of Columbia, Indiana.
Frequently Asked Questions
What is clinical trial NCT06275360 about?
NCT06275360 is a clinical study titled "Repositioning Immunotherapy in VetArans With Lung Cancer". This study is a multicenter Phase II single arm trial to assess the safety and efficacy of chemotherapy and immunotherapy followed by radiotherapy in patients with unresectable Stage III NSCLC.
What is the current status of trial NCT06275360?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 25 participants. The study started on 2024-03-01. Estimated completion is 2030-03-31.
What conditions does trial NCT06275360 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT06275360?
The interventions under investigation include: Nivolumab (DRUG).
Who is sponsoring clinical trial NCT06275360?
This trial is sponsored by VA Office of Research and Development, which has 1,668 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06275360 being conducted?
This trial has 7 study locations across Connecticut, District of Columbia, Indiana, Michigan, Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.